Oric Pharmaceuticals
SOUTH SAN FRANCISCO, CA · Biotechnology · 133 employees
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regim
Funding history
- Funding Round — $264.0M — Feb 2026
- Venture - Series Unknown — $125.0M — Jan 2024
- Post-IPO Equity — $125.0M — Jan 2024
- Venture - Series Unknown — $85.0M — Jul 2023
Recent signals
- Mar 31, 2026: SEC 8-K (8.01): On March 31, 2026, ORIC Pharmaceuticals, Inc. presented a program update regarding rinzimetostat (ORIC-944), specifically discussing recent dose optimization data from the ongoing Phase 1b trial. This update provides significant insights into the trial's progress and potential implications for the treatment’s efficacy. The detailed findings were shared in a presentation attached as Exhibit 99.1, illustrating the updated data and methodologies applied. The event is crucial as it could impact future developments in the company's product offerings and clinical strategies.
- Feb 23, 2026: Raised $264.0M in Funding Round
- Jul 16, 2024: ORIC Pharmaceuticals Announces Clinical Collaborations with Bayer and Johnson & Johnson for Prostate Cancer Treatment
- Jan 30, 2024: Raised $125.0M in Venture - Series Unknown
- Jan 24, 2024: Raised $125.0M in Post-IPO Equity
- Jul 05, 2023: Raised $85.0M in Venture - Series Unknown
See plans & pricing → Track Oric Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.